CHICAGO--(BUSINESS WIRE)--Researchers and scientists rely on antibodies to further research in cancer, neuroscience, immunology, molecular biology and more. But according to a 2015 survey by The Scientist, over 75 percent of researchers are replacing failed antibodies on a routine basis. Given the importance of successful antibodies, and in an effort to help drive accountability within the industry, Proteintech Group, the benchmark in antibodies, has announced they will exchange any competitor’s failed research antibody for the equivalent antibody from their own catalog at no charge. The original antibody manufacturer has launched this program as challenge to the industry to improve scientific reproducibility, with confidence that the replacement antibody will work correctly.
The research antibody market is a $2 billion industry, supplied by approximately 300 companies, according to Nature. When antibodies bind to the wrong proteins or bind in other unintended ways, experimental results become inaccurate, inconclusive or irreproducible. The Antibody Exchange Program by Proteintech reverses setbacks by providing a free replacement for any antibody that fails for any reason. Proteintech is the first antibody supplier to offer an exchange for competitor’s failed antibodies at no cost to the researcher.
“Antibodies can fail for a variety of reasons—from poor antibody quality to experimental error—but regardless of the cause, if it doesn’t perform, the scientist cannot move forward in their work,” said Katie Bellows, vice president of U.S. operations and customer service director at Proteintech. “Our Antibody Exchange Program ensures that if antibodies fail for any reason, they can continue their research as soon as possible.”
When creating antibodies, design, manufacturing and quality control practices vary widely so researchers typically purchase several antibodies and determine in their own labs which one, if any, meet their experiments’ standards. Proteintech makes every single antibody in its catalog, 12,000 antibodies against 12,000 targets. Each product is unique and cannot be bought under a different label, and Proteintech can therefore provide technical specifications about their antibodies to support their claim that all replacement reagents will work properly and are original products.
The Antibody Exchange Program will continue through December 31, 2015. New and existing customers are both welcomed to participate. Interested individuals are encouraged to visit abexchange.ptglab.com for more information.
About Proteintech Group
Proteintech is the benchmark for manufacturing original antibodies. With an emphasis on developing antibodies from whole proteins, Proteintech provides researchers with unmatched reliability and reproducibility. Founded by scientists in 2001 after their continued frustration with failed experiments due to low-grade antibodies, Proteintech is on a path to foster better science by producing the highest quality antibodies for every known human protein. For more information, please visit www.ptglab.com.
